Halozyme Therapeutics (HALO) EBITDA Margin Growth (3y) (2013 - 2026)

Halozyme Therapeutics (HALO) EBITDA Margin Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin Growth (3y) (Qtr)
1 Alterity Therapeutics 814,307.08 Bn 814,307.05 Bn - -
2 Belite Bio 55,320.00 Bn 55,320.00 Bn - -
3 Quantum Biopharma 17,149.72 Bn 17,149.72 Bn - -
4 Legend Biotech 3,590.00 Bn 3,589.71 Bn 242.10 Mn -40,178.00
5 Akari Therapeutics 1,650.72 Bn 1,650.72 Bn - -
6 Evaxion A 1,522.09 Bn 1,522.07 Bn - -
7 Psyence Biomedical 229.39 Bn 229.38 Bn - -
8 Vertex Pharmaceuticals 113.09 Bn 105.85 Bn 2.59 Bn 530.00
9 Abivax 90.15 Bn 90.15 Bn - -
10 Halozyme Therapeutics 8.24 Bn 7.92 Bn 297.47 Mn 1,580.00

Historic Data

Download Data
DateValue
Mar 31, 2026 1,580.00
Dec 31, 2025 -6,161.00
Sep 30, 2025 2,166.00
Jun 30, 2025 3,980.00
Mar 31, 2025 -1,108.00
Dec 31, 2024 347.00
Sep 30, 2024 -900.00
Jun 30, 2024 -1,752.00
Mar 31, 2024 -822.00
Dec 31, 2023 -1,986.00
Sep 30, 2023 -2,083.00
Jun 30, 2023 -1,079.00
Mar 31, 2023 4,589.00
Dec 31, 2022 10,080.00
Sep 30, 2022 9,293.00
Jun 30, 2022 5,806.00
Mar 31, 2022 5,931.00
Dec 31, 2021 5,554.00
Sep 30, 2021 16,494.00
Jun 30, 2021 12,521.00